The compliance side of the war on drugs


In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.